Rishi S. Kotecha

Perth, WA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Is low a go for pediatric AML?

Is low a go for pediatric AML?

Journal: Blood

Published: July 02, 2026

Characteristics and outcome of T-cell/histiocyte-rich large B-cell lymphoma in childhood and adolescence: An international retrospective analysis.

Characteristics and outcome of T-cell/histiocyte-rich large B-cell lymphoma in childhood and adolescence: An international retrospective analysis.

Journal: British journal of haematology

Published: June 12, 2026

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.

Journal: Pediatric blood & cancer

Published: June 01, 2026

IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumors.

IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumors.

Journal: Science advances

Published: April 29, 2026

Menin inhibitors display differential in vitro sensitivity in KMT2A-rearranged infant acute lymphoblastic leukemia.

Menin inhibitors display differential in vitro sensitivity in KMT2A-rearranged infant acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma

Published: February 19, 2026

Shared PRAME epitopes are T-cell targets in NUT carcinoma.

Shared PRAME epitopes are T-cell targets in NUT carcinoma.

Journal: Journal for immunotherapy of cancer

Published: January 10, 2026

Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2026

Tracking Health Related Quality of Life From Diagnosis to Follow-Up Among Australian Children With Acute Lymphoblastic Leukaemia.

Tracking Health Related Quality of Life From Diagnosis to Follow-Up Among Australian Children With Acute Lymphoblastic Leukaemia.

Journal: Pediatric blood & cancer

Published: December 18, 2025

Optimising Asparaginase Use and Managing Hypersensitivity in Australasia-A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group.

Optimising Asparaginase Use and Managing Hypersensitivity in Australasia-A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group.

Journal: Journal of paediatrics and child health

Published: December 15, 2025

Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy.

Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy.

Journal: Leukemia & lymphoma

Published: December 04, 2025

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: October 26, 2025

Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia.

Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia.

Journal: Scientific reports

Published: October 14, 2025

Showing 1-12 of 135

Last Updated: 09/26/2026